<DOC>
	<DOCNO>NCT01822444</DOCNO>
	<brief_summary>Primary Objective : The primary objective validate previously identify predictive/prognostic genomic DNA expression biomarkers response combination bvz treatment K-ras mutant advance CRC ( CRC ) metastatic CRC ( mCRC ) . Secondary Objective : 1 . To test efficacy bvz combination FOLFOX patient newly diagnose advanced metastatic K-ras mutant CRC 2 . To determine progression free overall survival patient first line FOLFOX + bvz aCRC mCRC .</brief_summary>
	<brief_title>ANGIOPREDICT . ICORG 12-16 , V3</brief_title>
	<detailed_description>Study Design : Type Study : Exploratory , translational , multicenter multinational Phase II study . Patient Population : All patient intent-to-treat population aCRC mCRC , ( incurable conventional multimodality approach ) fulfil inclusion exclusion criterion . Number Patients : 224 Sample Type : Serial tissue blood sample collect ( week 0 ) , ( week 6 , month 3 6 ) end treatment ( month 12 ) .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Patients ≥ 18 year age . 2 . Patients diagnosed recurrent de novo , locally advanced ( unresectable ) metastatic adenocarcinoma colon rectum . 3 . Planned combination bevacizumab ( bvz ) treatment either : leucovorin , fluorouracil oxaliplatin ( FOLFOX ) capecitabine oxaliplatin ( XELOX ) leucovorin , fluorouracil irinotecan ( FOLFIRI ) capecitabine irinotecan ( XELIRI ) 4 . Naive bvz 5 . An evaluable site disease 6 . ECOG Performance status 0 , 1 , 2 7 . Adequate renal function show serum creatinine ≤ 1.5 x ULN GFR ≥ 50ml/min 8 . Adequate hematopoietic function [ white blood cell ( WBC ) count ≥ 3000/μl , absolute neutrophil count ( ANC ) ≥1500/μl , platelet ≥100 000/μl , haemoglobin level ≥ 9.0 g/dl ] 9 . Adequate end organ function , define follow : total bilirubin &lt; 1.5 x ULN , SGOT SGPT &lt; 3.0 x ULN ( case liver metastasis SGOT SGPT &lt; 5.0 x ULN ) 10 . Ability give sign informed consent prior screen procedure 11 . FFPE Tissue available 1 . Patient receive investigational product within 28 day first day study drug dose 2 . Patients familial and/or hereditary CRC 3 . CRC associate ulcerative colitis 4 . Patient significant history noncompliance medical regimen inability grant reliable informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Advanced Colorectal Cancer</keyword>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Locally Advanced Colorectal Cancer</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Rectal Cancer</keyword>
</DOC>